Phase 3 COPD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men, or women who meet specific eligibility criteria set by the trial site
- People who have a higher-than-normal level of a type of white blood cell called eosinophils, measured through a blood test
- People who have been diagnosed with moderate to severe COPD for at least one year, confirmed by specific breathing test results
- People who have had exactly one moderate COPD flare-up (worsening of symptoms) in the past 12 months, plus at least one additional risk factor for future flare-ups — such as significant breathlessness, a high COPD symptom score, reduced lung function, or a long-term chesty cough with mucus
- People who are current or former cigarette smokers with a smoking history of at least 10 pack-years (confirm with trial site for how this is calculated)
- People who have been using two or three inhaler medications together for at least 3 months, as assessed by the treating doctor
- People with a body mass index (BMI) of 16 or above
Who may not be able to join:
- People whose main lung condition is something other than COPD, as judged by the treating doctor
- People who currently have, or have previously been diagnosed with, asthma (though people whose childhood asthma fully resolved before age 18 and has not returned may still be considered)
- People with other significant lung diseases where COPD is not the primary diagnosis
- People who have had more than one moderate flare-up, or any severe flare-up, of COPD in the 12 months before the first visit
- People who have had pneumonia, a COPD flare-up, or a lower respiratory tract infection in the four weeks before the first visit
- People who have previously had, or are planning to have, lung volume reduction surgery or a similar procedure
- People currently in the active phase of a pulmonary rehabilitation programme within four weeks before the first visit
- People who need a breathing support machine (such as BiPAP or CPAP) due to high carbon dioxide levels in their blood
- People who need continuous supplemental oxygen because of their COPD
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: GSK Clinical Trials, GlaxoSmithKline
Phone: 877-379-3718
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Annualized Rate of Moderate/Severe Exacerbations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.